Evommune, Inc. cash flow statement

In fiscal 2025, Evommune, Inc.'s operations generated −$76.4m of cash; it spent $235,000 on capital projects, leaving free cash flow of −$76.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Evommune, Inc.: cash flow statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−58	−76	−74
Depreciation and amortisation	1	1	1
Stock-based pay	2	6	13
Capital spending	0	0	1
Free cash flow	−58	−77	−75
Free cash flow after stock pay	−60	−83	−87

US$ millions unless shown otherwise. Fiscal quarters.

Evommune, Inc.: cash flow statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−19	−24	−26	−10	−17	−28	−20
Depreciation and amortisation	−0	0	0	1	−0	0	0
Stock-based pay	0	1	1	1	4	3	5
Capital spending	0	0	0	0	0	0	0
Free cash flow	−19	−24	−26	−10	−17	−28	−20
Free cash flow after stock pay	−19	−24	−27	−10	−21	−31	−25

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CRBU vs EVMN EVMN vs IRD EVMN vs RLAY

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Evommune, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evommune, Inc.